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Detection of IgG and IgM antibodies is commonly performed for the diagnosis of infection with Toxoplasma gondii. We determined 
the accuracy of the Elecsys Toxo IgG and IgM test at four European laboratories compared to local reference methods. Coefficients 
of variation for reproducibility ranged from 1.0 to 6.5% for IgG and from 0.8 to 3.2% for IgM. Seroconversion panels revealed high 
overall concordance with the reference tests. The Elecsys test detected IgG antibodies earlier than the Cobas Core IgG test in 19 of 
47 panels; persisting IgM antibodies were observed in the VIDAS but not the Elecsys test in five of 47 panels. In 31.4% of latent 
stage sera with persistent IgM antibodies (positive LIASON IgM), the Elecsys IgM test gave negative results indicating increased 
“clinical” specificity. Sensitivity and specificity of the Elecsys IgG assay ranged from 99.45 to 100% and 87.50–99.80%, respec-
tively, and 91.11–95.74 and 98.45–99.79% for the Elecsys IgM assay, respectively.
  In conclusion, excellent reproducibility and accuracy make the Elecsys Toxo G and M tests highly suitable for the detection of 
anti-T. gondii IgG and IgM antibodies. The lower detection rates for persistent IgM in the Elecsys IgM test increase “clinical” 
specificity and decrease the need for follow-up testing.
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Introduction
Infection with the protozoan parasite Toxoplasma gondii 
typically does not result in signs or symptoms of the in-
fection [1]. However, in rare cases, primary infection may 
lead to lymphadenitis or retinochoroiditis [1, 2]. Primary 
infection during pregnancy carries the risk of transmis-
sion of the parasite to the fetus, and the rate of transmis-
sion and severity of sequelae in the fetus are dependent 
on the age of gestation when infection is acquired [1]. De-
lays in diagnosis caused by long intervals between test-
ing may result in fetal infection, whereas early pre natal 
treatment reduces the risk for development of cerebral 
lesions and retinochoroiditis [3, 4]. In immunocompro-
mised patients, reactivation of the infection causes severe 
neurological damage and death if left untreated. In these 
patients, the presence of IgG but not IgM antibodies in-
dicates latent infection and identifi es patients at risk for 
reactivation; in contrast, the detection of IgG and IgM 
antibodies is key for the diagnosis of acute infection in 
immunocompetent patients [1]. Enzyme-immunoassays 
for the detection of anti-T. gondii IgG and IgM antibodies 
have been developed with high clinical accuracy; in most 
laboratories, these tests are routinely used [5, 6].
The Elecsys Toxo IgG and IgM tests (Roche Diagnos-
tics, Rotkreuz, Switzerland) are fully automated enzyme-
immunoassays using chemiluminescence for the measure-
ment of anti-T. gondii IgG and IgM antibodies [7–9]. The 
aim of this study was to validate the Elecsys Toxo IgG and 
IgM assays in four European laboratories using different 
panels of sera with known serological status as well as a 
large number of prospectively collected sera. Results indi-
cate that the Elecsys Toxo IgG and IgM tests are highly re-
producible and accurate allowing detection of Toxoplasma 
IgG and IgM antibodies.
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Materials and methods
The present clinical study was performed to validate the 
accuracy of the Elecsys Toxo IgG and IgM tests. In ad-
dition to a reproducibility and cross-reactivity study, we 
performed clinical studies using seroconversion panels 
from patients with known serology status, and a large 
European multicenter study using prospectively collected 
consecutive sera as well as archived sera with known se-
rology status.
Reproducibility study
Reproducibility was determined using human sera, Elec-
sys reagents, and controls in a modifi ed protocol of the 
National Committee for Clinical Laboratory Standards 
(NCCLS). Panels consisted of fi ve members: human sera 
either negative (n = 1) or positive (n = 2) for anti-T. gondii 
antibodies and controls designed to give negative (n = 1) 
to low positive (n = 1) results. Within run and between 
run reproducibility were determined with six daily runs for 
10 days.
Potentially cross-reacting sera
A total of 455 potentially cross-reacting sera were tested 
with the Elecsys Toxo IgM and a comparator IgM test. 
Sera contained antibodies against HAV, HBV, HCV, HIV, 
CMV, EBV, HSV, VZV, rubella, Treponema pallidum, 
 malaria, Entamoeba histolytica, Chlamydia trachoma-
tis, and Neisseria gonorrhoeae; autoantibodies (AMA, 
ANA); and elevated titers against rheumatoid factor, or 
were obtained after vaccination against HBV and infl u-
enza.
Seroconversion panels and sera from patients
with latent infection
Seroconversion panels were obtained from pregnant 
women in Marseille and Paris. Pregnant women had been 
tested under the French screening program for toxoplas-
mosis mandating screening of all pregnant women during 
the fi rst trimester of pregnancy and monthly controls if the 
fi rst serology is negative. Panels consisted of at least three 
and up to fi ve consecutive sera obtained shortly before or 
early after infection. The stage of infection had been es-
tablished using IgG and IgM Toxoplasma tests combined 
with tests for IgA and avidity and/or differential aggluti-
nation antibodies.
Sera obtained from patients during the latent stage 
of infection (>3 months) were used to evaluate the 
persistence of anti-T. gondii IgM antibodies compared 
to the Liason Toxo IgM test (DiaSorin, Saluggia, It-
aly). All sera had high avidity Toxoplasma IgG anti-
bodies.
Method comparison studies
Four European sites participated in the method compari-
son studies. All reference tests performed at the sites (Co-
bas Core Toxo, VIDAS Toxo, Advia Toxo, Platelia Toxo, 
and AxSym Toxo) were performed as recommended by the 
manufacturers.
A total of 492 samples were tested at the Toxoplasma 
Consulting Laboratory, Institute for Microbiology and 
Hygiene at the Charite Medical School in Berlin, Germa-
ny by the Elecsys Toxo G assay for Toxoplasma-specifi c 
IgG-antibodies compared to the VIDAS Toxo IgG assay 
(Biomerieux, Nürtingen, Germany). These included 247 
repository samples from patients either uninfected (25), 
with remote (4), latent (182), or acute infections (34). A 
total of 496 sera were tested by the Elecsys Toxo M assay 
compared to the VIDAS Toxo IgM assay. At the CHUV in 
Lausanne, Switzerland, 250 routine sera and 250 reposi-
tory sera from patients with remote (50), latent (50), or 
acute (50) infections as well as 50 sera with potentially 
cross-reactive antibodies were tested in the Elecsys Toxo 
G and M compared to the VIDAS Toxo IgG and IgM as-
says (Biomerieux).
Lastly, 40 frozen mother–child serum sets obtained 
at birth were analyzed to detect congenital infection us-
ing immunoelectrophoretic profi les (ELIFA). Overall, 
120 specimens were available (between 1 and 5 speci-
mens (average 2) from the newborns). Elecsys Toxo G 
and M results were compared to Toxoscreen DA IgG 
(Bio Mérieux) and ISAGA titers (BioMérieux), respec-
tively.
In the Laboratory of Parasitology and Mycology at 
the Hôpital de la Timone in Marseille, France, 526 sera 
were tested using the Elecsys Toxo G assay compared to 
the Cobas Core Toxo IgG (Roche Diagnostics, Rotkreuz, 
Switzerland) assay; there were 200 routine sera and 326 
repository sera from patients either uninfected (54), with 
remote (50), latent (52), or acute infections (50); 32 po-
tentially cross-reactive sera were also included. IgM anti-
body results were compared in 526 sera between the Elec-
sys Toxo IgM and VIDAS Toxo IgM assay. In addition, 
83 sera obtained from 25 seroconverting pregnant wom-
en were tested. A total of 508 sera were tested in Paris, 
France, using the Elecsys Toxo IgG assay compared to the 
Platelia Toxo IgG assay (Bio-Rad, Marnes-la-Coquette, 
France). There were 198 routine sera and 308 repository 
sera from patients being either uninfected (52), or with 
remote (50), latent (52), or acute infections (50); 13 po-
tentially cross-reactive sera were also included. A total of 
506 sera were tested using the Elecsys Toxo M and Plate-
lia Toxo IgM assays. In addition, 73 sera from 24 pregnant 
women with seroconversions were tested.
Resolution of discordant results
Predefi ned algorithms specifi c to the testing sites were 
used for resolution of discordant test results between the 
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Elecsys Toxo IgG and IgM and the reference tests. In 
all cases of discordant results, a repeat run of both tests 
was performed initially. If discordant results persisted, 
additional tests including the Sabin Feldman Dye test 
(considered the gold standard for detection of anti-
T. gondii IgG antibodies [1, 10]), the highly sensitive 
direct agglutination test [11], and other commercially 
available enzyme immunoassays were used. The rule 
of majority was used to resolve discordant results at 
sites that performed more than two tests for the detec-
tion of anti-T. gondii IgG  antibodies. To resolve dis-
crepancies in IgM test results, additional IgM tests in-
cluding IgM immunofluorescence test and IgG avidity 
assays [5], in addition to reviewing available clinical 
information, were used. All comparator and reference 
tests were performed as recommended by the manu-
facturers.
Elecsys Toxo IgG and IgM assay
The Elecsys Toxo IgG test is a quantitative sandwich 
test based on recombinant surface antigen SAG1 (p30). 
The sample volume is 10 μl. The duration of the test 
is 18 min consisting of the following steps: 1) incuba-
tion of sample with biotinylated recombinant T. gondii-
specifi c antigen and T. gondii-specifi c recombinant an-
tigen labeled with a ruthenium complex; 2) incubation 
of streptavidin-coated microparticles; 3) magnetic cap-
ture, removal of unbound substances, chemiluminescent 
emission measured by a photomultiplier; and 4) deter-
mination of results via a calibration curve standardized 
against the 3rd International Standard (TOXM NIBSC, 
UK). The cut-off is 3 IU/ml; results ≥1–2.9 IU/ml are 
considered indeterminate. No cross-reactivity was ob-
served with sera positive for HIV, HBV, HCV, CMV, 
HSV, VZV, EBV, ParvoB19, rubella, chlamydia, ma-
laria, and syphilis.
The Elecsys Toxo IgM test is a μ-capture test based 
on polymeric structure of the recombinant surface anti-
gen SAG1. Toxoplasma IgG antibodies are removed by 
capture to unlabeled monomer SAG1. The sample vol-
ume is 10 μl. The duration of the test is 18 min consist-
ing of the same steps as described above for the IgG test. 
The cut-off is 1.0; results >0.8–0.99 are considered in-
determinate. No cross-reactivity was observed with sera 
positive for HIV, HAV HBV, HCV, CMV, HSV, VZV, 
EBV, rubella, chlamydia, malaria, syphilis, AMA, and 
ANA.
Statistical analyses
Relative sensitivities and relative specifi cities includ-
ing confi dence intervals (CI) were calculated for the 
comparison of results after resolution of discrepancies. 
Samples with indeterminate results in any method were 
not included in the performance calculations.
Results
Reproducibility
The coeffi cients of variation for within run and in between 
run reproducibility for the detection of IgG anti-T. gon-
dii antibodies using human sera and controls ranged from 
1.9 to 2.5% and 2.7 to 4.0%, respectively; the coeffi cients 
of variation for within run and in between run reproduc-
ibility for the detection of IgM anti-T. gondii antibodies 
ranged from 1.1 to 2.2% and 2.5 to 5.4%, respectively.
Potentially cross-reacting sera
Among 455 sera with potentially cross-reacting antibod-
ies against a variety of infectious agents, rheumatoid fac-
tor, other autoantibodies or post-vaccination antibodies, 
the Elecsys Toxo IgM test gave positive results in four 
(AMA; malaria, EBV, VZV) of 455 cases. In two (AMA, 
VZV) of these cases, a comparator anti-T. gondii IgM test 
also gave positive results; three additional sera (AMA, 
malaria, anti-HBc IgM) also gave positive results in the 
comparator but not the Elecsys IgM test.
Seroconversion panels
Forty-seven seroconversion panels consisting of three to 
fi ve sera each were tested in the Elecsys Toxo IgG and 
IgM tests compared to the Cobas Core IgG and VIDAS 
or Platelia IgM tests. Concordant results were observed 
in the majority of panels (28/47). Discordant results ob-
served when comparing the IgG and IgM test results are 
listed in Table 1. In 19 of 47 panels with discordant re-
sults, IgG seroconversion was detected earlier in the Elec-
sys Toxo IgG compared to the comparator IgG tests. In 
16 of 19 cases, the Elecsys Toxo IgG test gave an ini-
tial intermediate result while the Cobas Core (n = 8 in 
Marseille) or Platelia IgG (n = 8 in Paris) test remained 
negative until the following blood draw (performed be-
tween 1 and 8 weeks later); in three additional cases, the 
Elecsys test gave an initial positive result while the Cobas 
Core or Platelia IgG test remained negative until the fol-
lowing blood draw. We also observed higher IgG titers as 
expressed in IU/ml compared to the comparator IgG tests 
(data not shown). There was 100% agreement between 
results in the Elecsys Toxo IgM and VIDAS Toxo IgM 
tests (Marseille); in two of 22 panels (Paris), the Plate-
lia IgM test gave a positive result while the Elecsys Toxo 
IgM test remained negative (a concordant positive result 
was observed in the follow-up sera obtained between 2 
and 3 weeks later). Of interest, these two sera also tested 
initially negative with the VIDAS Toxo IgM test.
In fi ve sera, we observed the disappearance of IgM 
antibodies in the Elecsys IgM test (4.5–36 weeks after se-
roconversion) whereas the VIDAS test continued to give 
positive results.
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These results point towards an increased sensitivity for 
the detection of IgG antibodies in the Elecsys compared 
to the Cobas Core and Platelia tests. In addition, the Elec-
sys IgM test appeared to show shorter persistence of IgM 
 antibodies.
Sera with persistent anti-T. gondii IgM antibodies
A panel of 35 sera from subjects with latent infections (>3 
months post infection as confi rmed by the presence of high 
IgG avidity antibodies) and positive IgM titers in the Li-
aison IgM test was tested with the Elecsys Toxo IgM and 
Cobas Core test (Table 2). Twenty-four of 35 sera gave 
concordant positive results between the Elecsys Toxo IgM 
and Liaison Toxo IgM test; however, in 11 sera, IgM an-
tibodies were undetectable using the Elecsys Toxo IgM 
test. Elecsys Toxo IgM and Cobas Core IgM tests showed 
23 concordant positive and nine concordant negative re-
sults. These results further underline the tendency towards 
shorter persistence of positive Elecsys IgM results high 
Table 1.  Discordant results in seroconversion panels (n = 25 in Marseille, n = 22 in Paris) between Elecsys and comparator IgG 
and IgM tests
Result constel-
lation Elecsys/
comparator
IgG IgM
Marseille
(Elecsys vs. Cobas 
Core)
Paris
(Elecsys vs. 
Platelia)
Marseille
(Elecsys vs. 
VIDAS)
Paris
(Elecsys vs. 
Platelia)
Seroconversion 
(negative to positive)
−/+ 0 0 0 2*
±/− 8 8 0 0
+/− 1 2 0 0
Disappearance of 
antibodies in f/up sera 
(positive to negative)
−/+ 0 0 5** 0
±/− 0 0 0 0
+/− 0 0 0 0
*VIDAS IgM also gave negative results in the same sera
**After 4–36 weeks
Table 2. Detection of anti-T. gondii IgM antibodies in patients with latent Toxoplasma infection
(>3 month post infection as indicated by the presence of high IgG avidity antibodies)
Serum no. Liaison Toxo IgM
(pos.: >10)
Elecsys Toxo IgM
(pos.: >1.0, neg.: <0.8)
Cobas Core IgM
(pos.: >100%, neg.: <90%)
1 11.5 (+)* 0.45 47.70
2 37.0 (+) 1.89 (+) 251.50 (+)
3 12.0 (+) 1.59 (+) 171.80 (+)
4 12.0 (+) 0.89 156.50 (+)
5 80.0 (+) 1.50 (+) 274.0 (+)
6 11.0 (+) 0.43 30.80
7 14.0 (+) 0.27 28.50
8 15.0 (+) 1.48 (+) 155.70 (+)
9 11.0 (+) 3.15 (+) 291.30 (+)
10 19.0 (+) 2.59 (+) 147.70 (+)
11 18.0 (+) 1.47 (+) 192.50 (+)
12 14.0 (+) 0.75 94.30
13 14.0 (+) 1.68 (+) 90.80
14 39.0 (+) 1.70 (+) 399.40 (+)
15 28.0 (+) 1.88 (+) 185.10 (+)
16 75.0 (+) 1.58 (+) 407.20 (+)
17 30.0 (+) 0.22 10.30
18 19.0 (+) 7.14 (+) 564.70 (+)
19 15.0 (+) 3.75 (+) 409.8 (+)
20 14.0 (+) 0.39 36.10
21 13.0 (+) 0.24 13.70
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compared to comparator IgM tests indicating increased 
“clinical” specifi city.
Method comparison studies
The multicenter method comparison study was performed 
at four European sites. Sites compared the performance 
of the Elecsys Toxo IgG and IgM tests to reference tests 
routinely performed in the respective laboratories. Results 
of the multicenter comparative study are presented by an-
tibody class and site.
Comparison of IgG results
Berlin, Germany
A total of 498 sera were tested using the Elecsys Toxo 
IgG and the VIDAS Toxo IgG tests (Table 3). Among 
these, 358 (71.89%) showed concordant positive and 105 
(21.08%) concordant negative results. There were 18 
 VIDAS negative/Elecsys positive, two VIDAS positive/
Elecsys negative, four Elecsys grey zone/VIDAS negative, 
and 11  VIDAS grey/Elecsys positive test results. Among 
the Elecsys positive/VIDAS negative samples, three of 
18 showed VIDAS positive results when retested and, thus, 
were considered concordant positive. After discordant test-
ing, the relative sensitivity of the Elecsys Toxo IgG test was 
99.45% (CI 98.02–94.45%) and the relative specifi city was 
87.5% (CI 80.22–92.83%) (Table 3). 
Lausanne, Switzerland
Five hundred sera were tested in the Elecsys Toxo IgG 
and VIDAS Toxo IgG test. Results are shown in Table 3. 
A total of 219 (43.8%) sera gave concordant positive and 
256 (51.2%) concordant negative results. There were nine 
VIDAS negative/Elecsys positive, one VIDAS positive/
Elecsys negative, four Elecsys grey zone/VIDAS nega-
Table 3. Relative sensitivity and relative specificity of the Elecsys Toxo G test compared to commercially available reference IgG 
assays before and after resolution of discordant results
Site Comparator assay IgG before resolution IgG after resolution
Sensitivity (CI) 
in %
Specificity (CI)
in %
Sensitivity (CI) 
in %
Specificity (CI) 
in %
Berlin VIDAS 99.44(97.51–99.98)
85.37
(79.77–92.49)
99.45
(98.02–94.45)
87.5
(80.22–92.83)
Lausanne VIDAS 99.55(97.49–99.99)
96.6
(93.65–98.44)
99.55
(97.49–99.99)
99.49
(96.18–99.59)
Marseille Cobas Core 99.29(97.45–99.9)
96.55
(93.32–98.5)
100
(98.69–100)
99. 57
(97.61–99.99)
Paris Platelia 99.56(97.58–99.99)
94.49 
(90.92–96.95)
100
(n.d.)
100
(n.d.)
n.d., CI not determined. For specific results of discrepant testing, see the Results section of the article
Serum no. Liaison Toxo IgM
(pos.: >10)
Elecsys Toxo IgM
(pos.: >1.0, neg.: <0.8)
Cobas Core IgM
(pos.: >100%, neg.: <90%)
22 16.0 (+) 10.03 (+) 564.70 (+)
23 45.0 (+) 3.45 (+) 535.50 (+)
24 15.0 (+) 1.40 (+) 228.80 (+)
25 26.0 (+) 2.95 (+) 414.10 (+)
26 11.0 (+) 0.20 17.40
27 10.0 (+) 1.89 (+) 191.0 (+)
28 119.0 (+) 2.45 (+) 397.7 (+)
29 12.0 (+) 1.82 (+) 132.80 (+)
30 22.0 (+) 4.03 (+) 564.70 (+)
31 10.0 (+) 1.22 (+) 81.90
32 44.0 (+) 0.26 23.40
33 >150 (+) 5.78 (+) 564.70 (+)
34 14.0 (+) 3.94 (+) 519.80 (+)
35 42.0 (+) 0.30 31.90
*(+), positive result
Table 2. (cont.)
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tive, and 11 VIDAS grey zone/Elecsys positive, negative, 
or grey zone results. Among nine Elecsys positive/VIDAS 
negative samples, one sample gave VIDAS positive re-
sults upon testing, four samples were confi rmed positive 
by the Toxoscreen direct agglutination assay, and in three 
sera, the initial VIDAS negative result was confi rmed; no 
additional information was available for one serum. One 
 VIDAS positive and Elecsys negative result was con-
fi rmed as true positive. Thus, the relative sensitivity of 
the Elecsys Toxo IgG compared to the VIDAS test was 
99.55% (CI 97.49–99.99%) and the relative specifi city 
was 99.49% (CI 96.18–99.59%) (Table 3). 
Regarding mother–child pairs, concerning IgG, there 
was overall good agreement between the Elecsys Toxo 
IgG test and the comparator tests. One major discrepancy 
(positive by Elecsys Toxo IgG but negative by DA) was 
observed in a maternal sample; however, the titers in the 
Elecsys Toxo IgG test were 5.44 IU/ml (barely above cut 
off) and 4 IU/ml (negative) in the DA test. We also ob-
served six minor discrepancies (positive Elecsys Toxo 
IgG vs. grey zone DA test, or grey zone Elecsys Toxo IgG 
vs. negative DA test) among newborn samples. These re-
sults point towards a superior sensitivity of the Elecsys 
Toxo IgG test compared to DA reference test. This is fur-
ther supported by the observation that IgG in passively 
immunized children was detected up to 3 months longer 
in the Elecsys Toxo IgG compared to the DA test (data 
not shown).
Marseille
A total of 526 sera were tested in the Elecsys Toxo IgG 
and Cobas Core Toxo IgG tests (Table 3). There were 279 
(53.04%) concordant positive, 224 (42.59%) concordant 
negative, eight Elecsys positive/Cobas Core negative, two 
Elecsys negative/Cobas Core positive, three Cobas Core 
positive/Elecsys grey zone, and ten Elecsys grey zone/
Cobas Core negative results. In ten sera with discordant 
results, repeat testing (n = 3) or reference testing using 
the Sabin Feldman dye test or the highly sensitive direct 
agglutination assay confi rmed the Elecsys Toxo IgG posi-
tive/Cobas Core Toxo IgG negative results. Relative sensi-
tivity was 100% (CI 98.69–100%), and relative specifi city 
was 99. 57% (CI 97.61–99.99%) (Table 3).
Paris
Among 506 sera tested with the Elecsys Toxo IgG and the 
Bio-Rad Platelia Toxo IgG test, 227 (44.86%) sera gave 
concordant positive results and 240 (47.43%) sera gave 
concordant negative results (Table 3). There were 14 Elec-
sys positive/Platelia negative and one Elecsys negative/
Platelia positive tests; in all cases, the positive result was 
confi rmed as true positive using indirect immunofl uores-
cence. Thirteen Platelia negative/Elecsys grey zone, eight 
Platelia grey zone/Elecsys positive, and three Platelia grey 
zone/Elecsys grey zone tests were observed; in all cases, 
Elecsys results were confi rmed as true positive or indica-
tive of seroconversion. The relative sensitivity of the Elec-
sys Toxo IgG test compared to the Platelia Toxo IgG test 
was 99.56% (CI 97.58–99.99%), and the relative specifi c-
ity was 94.49% (CI 90.92–96.95%) (Table 3).
Comparison of IgM results
Berlin
A total of 496 sera were used to compare the Elecsys and 
VIDAS Toxo IgM tests (Table 4). About 376 (75.81%) 
concordant negative and 67 (13.51%) concordant positive 
results were observed among 496 sera. There were four 
VIDAS negative/Elecsys positive, 23 VIDAS positive/
Elecsys negative, and 26 sera with grey zone results. After 
resolution of discordant results, the relative sensitivity was 
91.11% (CI 83.23%–96.08%) and the relative specifi city 
was 99.21% (CI 97.71–99.84%) (Table 4).
Lausanne
Among 500 sera tested with the VIDAS Toxo IgM and 
Elecsys Toxo M tests, we observed 381 (76.2%) concor-
dant negative and 83 (16.6%) concordant positive results; 
six sera were VIDAS negative/Elecsys positive, 11 were 
VIDAS positive/Elecsys negative, and 19 gave grey zone 
results (Table 4). IgM immunofl uorescence test results in 
all but one VIDAS positive/Elecsys negative sample were 
negative; ISAGA IgM was very low positive or even nega-
tive. In four cases, an acute infection was diagnosed while, 
in the other seven cases, the VIDAS Toxo IgM most likely 
detected persisting IgM antibodies turning the negative 
Elecsys Toxo IgM results a true negative result. Follow-
ing resolution of discrepant results, the relative sensitivity 
was 95.74% (CI 89.46–98.83%) and the relative specifi c-
ity was 98.45% (CI: 96.66–99.43%) (Table 4).
In mother–child paired specimens, we observed three 
major and nine minor discrepancies (data not shown). In 
maternal sera, all discrepancies indicated a lower sensi-
tivity of Elecsys Toxo IgM test compared to ISAGA. In 
newborn sera, there were four major discrepancies also 
pointing towards a decreased sensitivity of the Elecsys 
Toxo IgG test compared to ISAGA; congenital infection in 
three of four newborns was confi rmed by the presence of 
IgA antibodies, positive immune-electrophoresis profi les 
by ELIFA, or the presence of Toxoplasma DNA in amni-
otic fl uid.
Marseille
Comparing the Elecsys Toxo M with the VIDAS Toxo 
IgM tests on 526 sera in Marseille, we found 334 (63.5%) 
concordant negative and 143 (27.19%) concordant posi-
tive results (Table 4). Four samples showed VIDAS nega-
tive/Elecsys positive, 21 VIDAS positive/Elecsys nega-
tive, and 24 grey zone results. After resolution, relative 
specifi city was 99.11% (CI 97.43–99.82%) and relative 
sensitivity was 93.13% (CI 88.03–96.52%) (Table 4).
Paris
A total of 506 sera were tested in a method comparison 
between the Platelia Toxo IgM and Elecsys Toxo IgM test 
P. Meylan et al.
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in Paris (Table 4). About 325 (64.23%) sera tested con-
cordant negative, and 149 (29.45%) sera tested concordant 
positive; there were one Platelia negative/Elecsys positive 
and 19 Platelia positive/Elecsys negative sera; of 12 grey 
zone results in the Elecsys test, eight were positive and four 
were negative in the Platelia IgM test. After resolution, the 
relative sensitivity was 95.51% (CI 90.97–98.18%) while 
the relative specifi city was 88.69% (CI: 82.9–93.05%) 
(Table 4).
Discussion 
Depending on the patient’s immune status and on the 
disease setting, the diagnosis of infection with T. gondii 
can be established with a variety of techniques. Serologi-
cal tests are performed to determine the immune status in 
pregnant women and in organ donors or transplant recipi-
ents [1, 5, 12]. In patients with lymphadenopathy, uveitis, 
or retinochoroiditis and in newborns, serologic testing is 
used to diagnose toxoplasmosis [1, 5]. Whereas some Eu-
ropean countries including France have a policy for the 
prevention of congenital toxoplasmosis using systematic 
serologic screening of pregnant women, other countries, 
i.e., Switzerland, have discontinued such screening pro-
grams [13]. In France, a fi rst serology is performed before 
the end of the fi rst trimester of pregnancy, and in IgM-
positive cases, further testing is performed to establish 
the diagnosis of acute infection resulting in treatment. In 
the case of a negative result, serologic testing is repeated 
every month until delivery. For screening and diagnostic 
testing in subjects with suspected infection with T. gondii, 
serological tests need to demonstrate a balance between 
sensitivity and specifi city; the interpretation of results also 
depends on the clinical setting [5].
In the present study, we investigated the accuracy of 
the Elecsys Toxo IgG and IgM tests using seroconversion 
panels and selected sera from subjects with latent infec-
tions. Furthermore, in a clinical trial at four European 
sites, a large number of banked sera with known results 
and prospectively collected routine sera were included. To 
compare results in a “real world” scenario, each site com-
pared results of the Elecsys tests with IgG and IgM tests 
routinely performed in the laboratory. Additional testing 
was performed to determine the true status of the subject 
in case of discordant results.
The Elecsys Toxo IgG and IgM tests demonstrated ex-
cellent accuracy compared to other IgG and IgM tests in 
all subsets of sera tested. A trend towards increased sen-
sitivity for the Elecsys Toxo IgG test was observed in the 
seroconversion panels since earlier seroconversion from 
negative to equivocal or from negative to positive was ob-
served compared to the Cobas Core and Platelia Toxo IgG 
tests. The sensitivity and specifi city for the detection of 
anti-T. gondii IgG antibodies ranged from 99.29 to 99.56% 
and were similar at the four sites. We also observed higher 
IgG titers as expressed in IU/ml compared to the com-
parator IgG tests (data not shown). Increased sensitivity 
in clinical settings is of importance since it may translate 
into earlier diagnosis of pregnant women in screening pro-
grams allowing for earlier treatment that is associated with 
improved outcome [3–5]; in addition, increased sensitiv-
ity in other clinical settings allows to diagnose and man-
age infection in more subjects [5]. Conversely, increased 
sensitivity may result in prolonged detection of passively 
transferred maternal IgG antibodies in newborns when us-
ing the Elecsys Toxo IgG.
The increased sensitivity for anti-T. gondii IgG anti-
bodies observed in the present multicenter study is in line 
with earlier report from smaller evaluations. Jost et al. [14] 
used immunoblotting to compare results in the Elecsys 
Toxo IgG and Platelia IgG test in pregnant women known 
to have seroconverted based on monthly monitoring. 
Among initial sera with IgM-positive results, 7.7% gave 
equivocal (92.3% negative) results for IgG in the Platelia 
IgG test compared to 69.2% equivocal (30.8% negative) 
IgG results in the Elecsys Toxo test. These results mirror 
results observed using seroconversion panels in the pres-
ent study and underline the high sensitivity of the Elecsys 
Toxo IgG test. When comparing to the Sabin–Feldman dye 
test, a high sensitivity and specifi city of 97.1 and 100.0%, 
respectively, and a positive and negative predictive value 
of 100.0% and 81.3%, respectively, were observed in an 
Austrian cohort of 927 pregnant women [7]. Thus, the 
Table 4. Relative sensitivity and relative specificity of the Elecsys Toxo M test compared to commercially available IgM assays 
 before and after resolution of discordant results using reference tests
Site Comparator assay IgG before resolution IgG after resolution
Sensitivity (CI) 
in %
Specificity (CI)
in %
Sensitivity (CI) 
in %
Specificity (CI) 
in %
Berlin VIDAS 74.44(64.16–83.06)
98.95
(97.33–99.71)
91.11
(83.23–96.08)
99.21
(97.71–99.84)
Lausanne VIDAS 88.30(80.03–94.01)
98.45
(96.66–99.43)
95.74
(89.46–98.83)
98.45
(96.66–98.43)
Marseille VIDAS 87.20(81.09–91.9)
98.82
(97.0–99.68)
93.13
(88.03–96.52)
99.11
(97.43–99.82)
Paris Platelia 88.69(82.9–93.05)
99.69
(98.3–99.99)
95.51
(90.97–98.18)
99.69
(98.3–99.9)
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Elecsys Toxo IgG and IgM tests are useful tools for fi rst-
line screening of infection with T. gondii. Van Helden [8] 
reported a sensitivity of 100% and a specifi city of 99.91% 
for the Elecsys Toxo IgG test in a cohort of 2936 clini-
cal routine samples compared to the ADVIA Centaur Toxo 
IgG test. Increased sensitivity of the Elecsys Toxo IgG 
test compared to comparator tests may result in anxiety 
when discordant results are observed. A newly developed 
neutralization test [15] and a commercially available West-
ern Blot [9] were used to resolve discrepancies; in both 
studies, the vast majority of Elecsys Toxo IgG positive/
comparator IgG negative results were confi rmed as true 
positive.
The sensitivity of the Elecsys Toxo IgM test was 
comparable to the comparator tests ranging from 99.45 
to 100%. The specifi city ranged from 87.5 to 99.57%; 
of interest, the markedly lower specifi city of 87.5% was 
only observed at one site. Decreased specifi city for IgM 
(and IgG) in Berlin compared to other sites is most likely 
caused by the type of laboratory (academic laboratory 
with reference laboratory certifi cation and comparably 
low number of “clinical routine” sera); such differences 
in accuracy when testing “clinical routine” sera vs. sera 
submitted for reference testing have previously been re-
ported by us [16].
Prusa et al. [7] compared the Elecsys IgM assay to 
the infection status and reported a sensitivity of 94.1%; 
the specifi city was 79.0%, and the positive predictive and 
negative predictive values were 40.7 and 98.9%, respec-
tively. Of interest, the seroconversion panels in the present 
study revealed two Elecsys Toxo IgM negative/compara-
tor IgM positive sera early. These results are of concern in 
a clinical setting since a delay in diagnosis and treatment 
may result; however, the highly accurate VIDAS IgM test 
also gave negative results in these two samples; in follow-
up sera obtained 2–3 weeks later, both the Elecsys and 
 VIDAS IgM tests gave positive results.
Persistence of anti-T. gondii IgM antibodies has been 
described by us [16, 17] and others [18, 19]. Using im-
munosorbent agglutination and immunofl uorescence tests, 
persistence of IgM antibodies has been observed for more 
than 2 years in up to 27% of pregnant women [20]. Inter-
estingly, we observed that the Elecsys Toxo IgM test dem-
onstrated shorter persistence compared to the VIDAS IgM 
test in sera from patients latently infected (>3 months) as 
well as in the seroconversion panels. This lower reactivity 
towards persistent Toxo IgM antibodies in samples from 
latently infected subjects has previously been reported [8] 
and may represent a clinical benefi t since fewer sera (with 
positive IgM) need to be further investigated using addi-
tional tests or follow-up sera (=increased clinical specifi c-
ity). Furthermore, unnecessary abortion has been shown 
to be prevented by appropriate use and interpretation of 
serological test results [21]. In newborns, we observed a 
relatively lower sensitivity of the Elecsys Toxo IgM test 
compared to ISAGA; this fi nding is confi rming the supe-
rior sensitivity of ISAGA compared to immunoassays for 
the detection of IgM in newborns [22, 23]. In clinical prac-
tice, a battery of tests is commonly used to diagnose con-
genital infection including immunoassays for IgG, IgM, 
and IgA antibodies as well as ISAGA and PCR. The value 
of IgM immunoassays for the diagnosis of congenital in-
fection should therefore be further investigated.
More recently, the Elecsys Toxo IgG avidity test was 
introduced to complete the diagnostic portfolio for T. gon-
dii. A comparison of the Elecsys Toxo IgG avidity assay 
with two commercially available comparator assays re-
vealed excellent performance characteristics to exclude 
recent infection [24]. Furthermore, the authors suggested 
investigating the value of very high and very low IgG 
avidity titers to exclude infections within the last 9 months 
or to confi rm recent infections, respectively.
In conclusion, the present study revealed excellent re-
producibility, no cross-reactivity, and excellent clinical ac-
curacy of the Elecsys Toxo IgG and IgM tests. Combined 
with the rapid, fully automated high-throughput workfl ow 
solutions on the Cobas systems, the Elecsys Toxo IgG and 
IgM thereby provide an attractive laboratory offering to 
screen for and diagnose infection with T. gondii.
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